[Use of reminyl (galantamine) in the treatment of dementia].

Abstract

Clinical efficacy and safety of reminyl monotherapy has been studied in patients with dementia of Alzheimer's and mixed vascular-degenerative types. The reminyl treatment has been conducted in dosage of 16 mg/kg daily during 6 months in 30 patients (20 female, 10 male) aged from 59 to 86 years. The results of the study revealed high efficacy of reminyl in the treatment of patients with mild and moderate dementia and good tolerability of the medication.

• Authors: K V Voronkova, O A Pylaeva, O V Mazal'skaia, I D Lemeshko, A S Petrukhin
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 106 Issue 3 Pg. 26-30 ( 2006) ISSN: 1997-7298 [Print] Russia (Federation)
• PMID: 16608108 (Publication Type: English Abstract, Journal Article)

Chemical References

• Cholinesterase Inhibitors
• Galantamine

Topics

• Aged
• Aged, 80 and over
• Alzheimer Disease (diagnosis, drug therapy)
• Cholinesterase Inhibitors (administration & dosage, therapeutic use)
• Dementia (diagnosis, drug therapy)
• Dementia, Vascular (diagnosis, drug therapy)
• Female
• Galantamine (administration & dosage, therapeutic use)
• Humans
• Male
• Middle Aged
• Psychiatric Status Rating Scales
• Time Factors
• Treatment Outcome